BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jun 28, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Microplasmin: Additional Phase III data

Additional data from the double-blind, U.S. Phase III TG-MV-006 trial in 326 patients showed that a single 125 µg intravitreal injection of microplasmin significantly increased the proportion of patients achieving a >=10 letter improvement in visual acuity from baseline to 6 months vs. placebo (25.5% vs. 11.3%, p<0.005). In patients diagnosed with full thickness macular hole (n=84), a significantly...

Read the full 271 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >